News
ABCL
3.900
-1.76%
-0.070
In the wake of AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest US$91m market cap drop, institutional owners may be forced to take severe actions
AbCellera Biologics Inc. Has a market cap of US$1.1b. The company has a large number of institutional investors in its share price. The top 8 shareholders of AbCellera biologics own 27% of the company. This suggests the company is sensitive to its own shareholders. The CEO of Abcellera Biologistics is the largest shareholder. It's worth looking at the company's ownership of shares to see if insiders are aligned with shareholders. AbCellERA Biologic's market cap has fallen 46% in the last year.
Simply Wall St · 2d ago
Weekly Report: what happened at ABCL last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at ABCL last week (0408-0412)?
Weekly Report · 04/15 09:13
AbCellera Presents Data On T-Cell Engagers Against Four Tumor Targets At AACR 2024
AbCellera announces new data on its T-cell engager programs at the American Association for Cancer Research. AbCellera is well-positioned to advance TCEs as a drug class by widening the therapeutic window and broadening the accessible target space. CD3-binding antibodies consistently generate T- cell engagers with potent tumor-cell killing and low cytokine release across multiple tumor targets.
Benzinga · 04/08 16:06
Weekly Report: what happened at ABCL last week (0401-0405)?
Weekly Report · 04/08 09:14
Weekly Report: what happened at ABCL last week (0325-0329)?
Weekly Report · 04/01 09:14
Weekly Report: what happened at ABCL last week (0318-0322)?
Weekly Report · 03/25 09:14
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
AbCellera will present at the Bloom Burton Healthcare Conference on April 16, 2024. A live audio webcast of the presentation will be available on abcellera's investor relations website. AbCellera discovers and develops antibody medicines for indications across therapeutic areas. The company's executives will present.
Barchart · 03/19 15:05
Weekly Report: what happened at ABCL last week (0311-0315)?
Weekly Report · 03/18 09:14
AbCellera gains on antibody collaboration with Biogen
AbCellera Biologics announces collaboration with Biogen to develop antibodies to treat neurological ailments. The agreement calls for the discovery of a novel target that would allow for the delivery of treatment through the blood brain barrier. AbCellera is up 3% in Monday trading.
Seeking Alpha · 03/11 16:23
Weekly Report: what happened at ABCL last week (0304-0308)?
Weekly Report · 03/11 09:14
This ETF Holds Stocks Insiders Want to Own
NASDAQ · 03/07 14:35
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
AbCellera will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research Annual Meeting 2024. AbCellera is developing molecules with the potential for improved efficacy and safety profiles for solid tumors. The company will present data on novel CD28-binding antibodies that can be used to optimize T- cell engagers.
Barchart · 03/05 15:30
Weekly Report: what happened at ABCL last week (0226-0301)?
Weekly Report · 03/04 09:14
AbCellera Biologics Insiders Added US$1.61m Of Stock To Their Holdings
AbCellera Biologics Inc. Insiders bought US$998k worth of shares in the last 12 months. The company has a 28% of the company, worth about US$418m. In the last year, AbCelleraBiologics insiders have bought up shares at higher prices. This suggests that the company is optimistic about its future. It's important to look at the number of insider transactions in a company. Abcellera Biologist's insider transactions over the past year are reassuring.
Simply Wall St · 02/29 11:02
AbCellera: Victim Of Its Own Success
AbCellera Biologics has faced declining royalty revenues and reduced demand for its R&D services. The company is a drug discovery company taking a technological approach to discovering and developing antibody therapies. AbCellera's success during the pandemic led to over-inflated investor expectations. The stock has been pressured by the combination of declining revenue and rising costs.
Seeking Alpha · 02/28 17:36
Weekly Report: what happened at ABCL last week (0219-0223)?
Weekly Report · 02/26 09:15
Peter Thiel Retires from AbCellera Board, Dr. Andrew Lo Steps In
TipRanks · 02/24 15:11
Peter Thiel resigns from AbCellera board for personal reasons
Healthcare Peter Thiel resigns from AbCellera board for personal reasons. Thiel did not inform the company that he had any disagreements with its operations, policies or practices. Thiel's resignation will reduce the number of directors on Ab cellera's board to five. Abcellera Biologics Inc. Said Peter Thiel plans to resign from its board of directors.
Seeking Alpha · 02/23 22:38
More
Webull provides a variety of real-time ABCL stock news. You can receive the latest news about Abcellera Biologics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ABCL
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.